Intestinal Microbial Dysbiosis in Chinese Infants With Short Bowel Syndrome With Different Complications

Multi-center Clinical Research About Standard Diagnosis and Treatment of Neonate Severe Digestive System Malformation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02699320

Acronym

MSBS

Enrollment

Registered

2016-03-04

Start date

2015-06-30

Completion date

2016-01-31

Last updated

2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications, Short Bowel Syndrome

Keywords

Short bowel syndrome, Intestinal microbiota, immune

Brief summary

There are no reports involved the intestinal microbiota from Chinese infants with short bowel syndrome (SBS) under different clinical status. Alterations in the microbiota are closely correlated with the bile acids and short chain fatty acids metabolism as well as the intestinal immunity. A relatively comprehensive profile composed of microbial structure, microbial metabolism products and immune biomarkers in SBS infants may facilitate a better therapy strategy to complications occurred in SBS children.

Detailed description

The investigators totally collected 26 fecal samples from 18 infants diagnosed with SBS during parenteral nutrition administration, and these samples were divided into three groups according to complications of enrolled patients at sampling time: asymptomatic group, central catheter-related blood stream infections group and liver injury group. 7 healthy infants with supplementary food were enrolled as control. Fecal microbiota, sIgA and calprotectin, bile acids and short chain fatty acids were also detected by 16S ribosomal ribonucleic acid (rRNA) gene sequencing, enzyme-linked immunosorbent assay and liquid/gas chromatography.

Interventions

OTHERComplications

Not involved

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 1 Years

Healthy volunteers

Inclusion criteria

* Infants with short bowel syndrome

Design outcomes

Primary

Measure	Time frame	Description
Microbial structure in SBS infants	up to 4 months	Fecal microbiota were detected by 16S rRNA gene sequencing.

Secondary

Measure	Time frame	Description
Metabolism products in SBS infants	up to 4 months	Bile acids and short chain fatty acids were detected by liquid/gas chromatography.
Immune biomarkers in SBS infants	up to 4 months	Secretary IgA and calprotectin were detected by enzyme-linked immunosorbent assay.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026